DGAP-News: Epigenomics AG: Epigenomics AG Publishes 2013 Annual Report and Provides Outlook for the Year 2014

DGAP-News: Epigenomics AG: Epigenomics AG Publishes 2013 Annual Report and 
Provides Outlook for the Year 2014

DGAP-News: Epigenomics AG / Key word(s): Final Results
Epigenomics AG: Epigenomics AG Publishes 2013 Annual Report and
Provides Outlook for the Year 2014

28.03.2014 / 08:30

---------------------------------------------------------------------

  - Company confirms preliminary financial results for the fiscal year
    ending December 31, 2013 announced on February 26, 2014

  - Prior to securing U.S. market approval for Epi proColon(R), Epigenomics
    provides an outlook for 2014, expecting revenue and net loss slightly
    increased compared to 2013

  - FDA Advisory Committee provides recommendations for Epigenomics'
    colorectal cancer screening blood test

  - Company will discuss financial results and positive outcome from
    committee meeting in more detail in today's conference for journalists,
    analysts and investors

Berlin (Germany) and Germantown, MD (U.S.A.), March 28, 2014 - Epigenomics
AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American
cancer molecular diagnostics company, announced that it has published today
the annual report for the fiscal year ending December 31, 2013 and an
outlook for the year 2014. The Company already published 2013 preliminary
financial results and operational highlights on February 26, 2014.

Epigenomics confirmed that revenue in 2013 increased by 53% to
approximately EUR 1.6 million (2012: EUR 1.0 million), operating loss
(EBIT) was significantly reduced by 40% to EUR 7.3 million (2012: EUR 12.1
million) and net loss was reduced by 39% to EUR 7.4 million (2012: EUR 12.2
million) which equals a loss per share of EUR 0.62 (2012: EUR 1.38). Cash
consumption in 2013 amounted to EUR 6.5 million (2012: EUR 10.9 million)
and year-end liquidity including marketable securities to EUR 8.0 million
(2012: EUR 2.7 million).

"2013 was a good year for Epigenomics. We were able to successfully
establish important strategic partnerships to support the commercialization
of our key product Epi proColon(R) following potential regulatory approval
in the U.S. and to develop new markets, for example China. In addition, we
significantly improved our financial position and increased our financial
flexibility by raising EUR 12.5 million, in a series of transactions," said
Dr. Thomas Taapken, CEO/CFO of Epigenomics. "We are pleased with the advice
of the FDA's Medical Devices Advisory Committee for our blood-based
colorectal cancer screening test that we announced yesterday. This
recommendation is a big milestone for the Company and we will discuss
results of the meeting in more detail during today's conference. We will
now define an approval path with the FDA to launch Epi proColon(R) in the
U.S. as soon as possible and believe we are best positioned to bring
sustainable value to our shareholders through prosperous product launches
in major markets."

Outlook for 2014

Prior to an approval of Epi proColon(R) as an IVD product in the U.S.
market, Epigenomics remains cautious and expects revenue in 2014 to
slightly increase from 2013 levels. Net loss for 2014 is expected to be in
the range of EUR 7.5 to 8.5 million. In line with the expected net loss
range, cash consumption for fiscal 2014 is projected at a slightly
increased level compared to 2013 in the range of EUR 7.0 to 8.0 million.
The complete annual report 2013 including an outlook for 2014 can be
downloaded from the Company's website under
http://www.epigenomics.com/en/news-investors/investors/financial-reports/2
013.html.

Epigenomics AG will host a conference for journalists, analysts and
investors today, March 28, 2014 from 1:00 pm to 2:30 pm CET at equinet Bank
AG, Gräfstrasse 97, Frankfurt am Main in German language followed by a
conference call starting at 3:00 pm CET in English language. Management
will discuss the detailed results for the financial year 2013 and provide
an update on the FDA Advisory Committee meeting. The conference call will
be webcasted and can be accessed on Epigenomics' website under
www.epigenomics.com.

-Ends-

Contact Epigenomics AG
Antje Zeise, Manager IR | PR
Epigenomics AG 
Kleine Praesidentenstrasse 1
10178 Berlin
Tel. +49 (0) 30 24345 368 
ir@epigenomics.com  
www.epigenomics.com 

For US press inquiries:
Epigenomics, Inc.
20271 Goldenrod Lane, Suite 2027
Germantown, Maryland 20876
pr@epigenomics.com

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer earlier
and more accurately, leading to improved outcomes for patients.
Epigenomics' lead product, Epi proColon(R), is a blood-based test for the
early detection of colorectal cancer, which is currently marketed in Europe
and is under regulatory review by the FDA for the U.S.A. Additionally, the
company markets its tissue assay for use in lung cancer diagnosis, Epi
proLung(R), in Europe. The Company's technology and products have been
validated through multiple partnerships with leading global diagnostic
companies and testing laboratories. Epigenomics is an international company
with operations in Europe and the U.S.A.

Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.


End of Corporate News

---------------------------------------------------------------------

28.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English                                                
Company:     Epigenomics AG                                         
             Kleine Präsidentenstraße 1                             
             10178 Berlin                                           
             Germany                                                
Phone:       +49 30 24345-0                                         
Fax:         +49 30 24345-555                                       
E-mail:      ir@epigenomics.com                                     
Internet:    www.epigenomics.com                                    
ISIN:        DE000A1K0516                                           
WKN:         A1K051                                                 
Listed:      Regulierter Markt in Frankfurt (Prime Standard);       
             Freiverkehr in Berlin, Düsseldorf, München, Stuttgart  
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
260215 28.03.2014                                                      
 
Press spacebar to pause and continue. Press esc to stop.